Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upper-limb Active Function and Botulinum Toxin A
2024-518147-37-00Phase 2Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of botulinum toxin type A in stroke and Muscle spasm (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Spastic co-contraction index (ICCS). Planned start Oct 2024; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
strokeMuscle spasm
Beyond the preview
Go deeper on 2024-518147-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518147-37-00.